Fragmin Licensed For Unstable CAD

10 March 1997

Pharmacia & Upjohn's low-molecular weight heparin product Fragmin(dalteparin sodium) is now licensed in the UK for the management of patients with unstable coronary artery disease. This is the first country to approve the new indication.

The recommended dosage of Fragmin for CAD is 120 IU/kg, given by subcutaneous injection every 12 hours over five to eight days. The data sheet recommends concomitant therapy with low-dose aspirin. The maximum recommended dose is 10,000 IU in 12 hours.

The new indication for Fragmin is based on the results of the FRISC and FRIC studies (Marketletters passim). Also ongoing is FRISC II, which is looking at longer-term outcomes when using Fragmin in unstable CAD.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight